Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHILLES: Secukinumab for Achilles Tendon Enthesitis in PsA and axSpA
NCT02771210Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2016
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and enthesitis comparing Secukinumab with Placebo -> Secukinumab (2 arms). Primary endpoint: Number (%) of Patients With Resolution of Achilles Tendon Enthesitis at 24 weeks. Started Aug 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)enthesitis
Beyond the preview
Go deeper on NCT02771210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02771210.